Revolution Medicines, Inc. - Common Stock (RVMD)

The Commissioner's National Priority Review vouchers aims to speed up the review process to just one to two months.

The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, and other conditions.

Wells Fargo's Timna Tanners initiated coverage on Martin Marietta Materials with an Equal-Weight rating and announced a price target of $620.

The FDA’s new National Priority Voucher pilot helps with faster drug reviews, cutting timelines from nearly a year to weeks.

Revolution Medicines reports positive results from daraxonrasib trials in metastatic pancreatic cancer, with strong response rates and consistent safety data.

Revolution Medicines (RVMD) missed Q2 2025 revenue and EPS estimates, reporting $0 revenue and a -$1.31 loss. Shares dropped 4.5% amid investor concerns, despite progress in Phase 3 trials for daraxonrasib.

Revolution Medicines signs a $2 billion funding deal with Royalty Pharma to support its RAS(ON) pipeline, including daraxonrasib development and launch.

Royalty Pharma will provide up to $1.25 billion to Revolution Medicines in exchange for a synthetic royalty on annual worldwide net sales of Daraxonrasib for a term of 15 years and a senior secured loan of up to $750 million.

Revolution Medicines shared Phase 1 data showing zoldonrasib's acceptable safety profile in KRAS G12D mutant solid tumors at AACR 2025.